Suchergebnisse - "Motta, Ilaria"

On tuberculosis and COVID-19 co-infection von Tadolini, Marina, García-García, José-María, Blanc, François-Xavier, Borisov, Sergey, Goletti, Delia, Motta, Ilaria, Codecasa, Luigi Ruffo, Tiberi, Simon, Sotgiu, Giovanni, Migliori, Giovanni Battista

Weitere Angaben

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis von Berry, Catherine, du Cros, Philipp, Fielding, Katherine, Gajewski, Suzanne, Kazounis, Emil, McHugh, Timothy D., Merle, Corinne, Motta, Ilaria, Moore, David A. J., Nyang’wa, Bern-Thomas

“… Background Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9–24 months duration, …”
Volltext

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis von Sweeney, Sedona, Berry, Catherine, Kazounis, Emil, Motta, Ilaria, Vassall, Anna, Dodd, Matthew, Fielding, Katherine, Nyang’wa, Bern-Thomas

“… Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following …”
Volltext

Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross‐sectional study in rural Burundi von Calcagno, Andrea, Motta, Ilaria, Milia, Maria Grazia, Rostagno, Roberto, Simiele, Marco, Libanore, Valentina, Fontana, Silvia, D'Avolio, Antonio, Ghisetti, Valeria, Di Perri, Giovanni, Bonora, Stefano

“… Aims In limited resource settings monitoring antiretroviral (ARV) treatment efficacy is restrained by the lack of access to technological equipment. The aim of …”
Volltext

Plasma miRNA‐based signatures in CRC screening programs von Zanutto, Susanna, Ciniselli, Chiara Maura, Belfiore, Antonino, Lecchi, Mara, Masci, Enzo, Delconte, Gabriele, Primignani, Massimo, Tosetti, Giulia, Dal Fante, Marco, Fazzini, Linda, Airoldi, Aldo, Vangeli, Marcello, Turpini, Francesca, Rubis Passoni, Giovanni Giuseppe, Viaggi, Paolo, Arena, Monica, Motta, Roberta Ilaria Olimpia, Cantù, Anna Maria, Crosta, Cristiano, De Roberto, Giuseppe, Iannuzzi, Francesca, Cassinotti, Andrea, Dall'Olio, Valentina, Tizzoni, Laura, Sozzi, Gabriella, Meroni, Emanuele, Bisanti, Luigi, Pierotti, Marco Alessandro, Verderio, Paolo, Gariboldi, Manuela

“… Colorectal cancer (CRC) screening programs help diagnose cancer precursors and early cancers and help reduce CRC mortality. However, currently recommended …”
Volltext

Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? von Motta, Ilaria, Calcagno, Andrea, Bonora, Stefano

“… Introduction: WHO global strategy is to end tuberculosis epidemic by 2035. Pharmacokinetic and pharmacogenetic studies are increasingly performed and might …”
Volltext

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis von Nyang’wa, Bern-Thomas, Berry, Catherine, Kazounis, Emil, Motta, Ilaria, Parpieva, Nargiza, Tigay, Zinaida, Solodovnikova, Varvara, Liverko, Irina, Moodliar, Ronelle, Dodd, Matthew, Ngubane, Nosipho, Rassool, Mohammed, McHugh, Timothy D., Spigelman, Melvin, Moore, David A.J., Ritmeijer, Koert, du Cros, Philipp, Fielding, Katherine

“… In this trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin was noninferior to standard care for rifampin-resistant tuberculosis …”
Volltext

Recent advances in the treatment of tuberculosis von Motta, Ilaria, Boeree, Martin, Chesov, Dumitru, Dheda, Keertan, Günther, Gunar, Horsburgh, Jr, Charles Robert, Kherabi, Yousra, Lange, Christoph, Lienhardt, Christian, McIlleron, Helen M, Paton, Nicholas I, Stagg, Helen R, Thwaites, Guy, Udwadia, Zarir, Van Crevel, Reinout, Velásquez, Gustavo E, Wilkinson, Robert J, Guglielmetti, Lorenzo

“… Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has …”
Weitere Angaben

The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis von Hasan, Tasnim, Medcalf, Ellie, Nyang'wa, Bern-Thomas, Egizi, Erica, Berry, Catherine, Dodd, Matthew, Foraida, Salah, Gegia, Medea, Li, Mengchun, Mirzayev, Fuad, Morgan, Hannah, Motta, Ilaria, Nguyen, Linh, Schumacher, Samuel, Schlub, Tim, Fox, Greg

“… Abstract Background Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel …”
Volltext

Liberty, Justice, and Victory: Abstract Nouns are Grammatically and Psychologically Feminine von Cervone, Carmen, Motta, Ilaria, Scatolon, Andrea, Cimmino Picone, Valentina, Maass, Anne

“… Grammatical gender generally implies disadvantages for women (e.g., the generic masculine leading to real-life invisibility of women). Diverging from this …”
Volltext

Tuberculosis and COVID-19 co-infection: description of the global cohort

“… Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the …”
Weitere Angaben

Ulcerative pyoderma gangrenosum in inflammatory bowel disease von Motta, Ilaria, Perricone, Giovanni

Weitere Angaben

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study von Calcagno, Andrea, Cusato, Jessica, Sekaggya-Wiltshire, Christine, von Braun, Amrei, Motta, Ilaria, Turyasingura, Grace, Castelnuovo, Barbara, Fehr, Jan, Di Perri, Giovanni, Lamorde, Mohammed

“… Unsatisfactory treatment outcomes have been reported in patients coinfected with HIV/tuberculosis (TB). The aim of this study was to assess the influence of …”
Weitere Angaben

Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis von Guglielmetti, Lorenzo, Khan, Uzma, Velásquez, Gustavo E., Gouillou, Maelenn, Abubakirov, Amanzhan, Baudin, Elisabeth, Berikova, Elmira, Berry, Catherine, Bonnet, Maryline, Cellamare, Matteo, Chavan, Vijay, Cox, Vivian, Dakenova, Zhanna, de Jong, Bouke Catherine, Ferlazzo, Gabriella, Karabayev, Aydarkhan, Kirakosyan, Ohanna, Kiria, Nana, Kunda, Mikanda, Lachenal, Nathalie, Lecca, Leonid, McIlleron, Helen, Motta, Ilaria, Toscano, Sergio Mucching, Mushtaque, Hebah, Nahid, Payam, Oyewusi, Lawrence, Panda, Samiran, Patil, Sandip, Phillips, Patrick P. J., Ruiz, Jimena, Salahuddin, Naseem, Garavito, Epifanio Sanchez, Seung, Kwonjune J., Ticona, Eduardo, Trippa, Lorenzo, Vasquez, Dante E. Vargas, Wasserman, Sean, Rich, Michael L., Varaine, Francis, Mitnick, Carole D.

“… In this trial, three 9-month, all-oral regimens were found to be noninferior to standard treatment (typically 18 to 24 months) for rifampin-resistant …”
Volltext

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial von Motta, Ilaria, Cusinato, Martina, Ludman, Andrew J, Lachenal, Nathalie, Dodd, Matthew, Soe, Moe, Abdrasuliev, Tleubergen, Usmanova, Ruzilya, Butabekov, Ilhomjon, Nikolaevna, Tigay Zinaida, Liverko, Irina, Parpieva, Nargiza, Moodliar, Ronelle, Solodovnikova, Varvara, Kazounis, Emil, Nyang'wa, Bern-Thomas, Fielding, Katherine L, Berry, Catherine

“… Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled …”
Weitere Angaben

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? von Sekaggya-Wiltshire, Christine, Chirehwa, Maxwell, Musaazi, Joseph, von Braun, Amrei, Buzibye, Allan, Muller, Daniel, Gutteck, Ursula, Motta, Ilaria, Calcagno, Andrea, Fehr, Jan S, Kambugu, Andrew, Castelnuovo, Barbara, Lamorde, Mohammed, Denti, Paolo

“… Antituberculosis drugs display large pharmacokinetic variability, which may be influenced by several factors, including body size, genetic differences, and …”
Weitere Angaben

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study von De Nicolò, Amedeo, Calcagno, Andrea, Motta, Ilaria, De Vivo, Elisa, D'Avolio, Antonio, Di Perri, Giovanni, Wiesner, Lubbe, Ebrahim, Isma-Eel, Maartens, Gary, Orrell, Catherine, McIlleron, Helen

“… Ritonavir-boosted darunavir (DRV/r) and dolutegravir (DTG) are affected by induction of metabolizing enzymes and efflux transporters caused by rifampicin …”
Weitere Angaben

Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? von Trentalange, Alice, Borgogno, Enrica, Motta, Ilaria, Antonucci, Miriam, Pirriatore, Veronica, Costa, Cecilia, Rossi, Giovanni, Barco, Ambra, De Nicolò, Amedeo, Piccioni, Pavilio, D'Avolio, Antonio, Bonora, Stefano, Di Perri, Giovanni, Calcagno, Andrea

“… •The majority of participants showed low rifampin and isoniazid plasmatic maximal concentrations at two early time points.•Ca. one-fifth of patients had …”
Volltext

A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs von Baietto, Lorena, Calcagno, Andrea, Motta, Ilaria, Baruffi, Katia, Poretti, Viviana, Di Perri, Giovanni, Bonora, Stefano, D'Avolio, Antonio

“… TB is currently the second cause of death among patients affected with infectious diseases. Quantification of drug levels in plasma and in cells where …”
Weitere Angaben

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation von Sweeney, Sedona, Laurence, Yoko V, Berry, Catherine, Singh, Maninder Pal, Dodd, Matthew, Fielding, Katherine, Kazounis, Emil, Moodliar, Ronelle, Solodovnikova, Varvara, Tigay, Zinaida, Liverko, Irina, Parpieva, Nargiza, Butabekov, Ilhomjon, Usmanova, Ruzilya, Rassool, Mohammed, Motta, Ilaria, Nyangweso, George Mokua, Jolivet, Pascal, Abdrasuliev, Tleubergen, Moe, Soe, Aw, Pei Sun, Samieva, Nazgul, Nyang'wa, Bern-Thomas

“… New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or …”
Volltext